Plain Language Summary: treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study)
This Plain Language Summary from Immunotherapy describes the results of a study called POETYK PSO-2. The study looked at a new treatment called Deucravacitinib for a skin condition known as plaque psoriasis.
Read the full article here.
To see a video where the author gives an overview of the Plain Language Summary, see below.
The original article on which this Plain Language Summary of Publication is based is titled ‘Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial’ and was published in the Journal of the American Academy of Dermatology. Read the original article here.